Trials / Unknown
UnknownNCT04221919
Different β -Blockers in STEMI and Primary PCI
Different β -Blockers in Patients With ST-segment Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 1,200 (estimated)
- Sponsor
- Qilu Hospital of Shandong University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Carvedilol, target dose: 50 mg daily; Bisoprolol, target dose: 10 mg daily; Metoprolol tartrate, target dose: 150 mg daily; Metroprolol succinate, target dose: 200 mg daily
Detailed description
The investigators will investigate the efficacy and safety of different β -blockers, as well as heart rate variability, in STEMI patients undergoing primary PCI.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | β -Blockers | Target doses of carvedilol, bisoprolol, metoprolol tartrate, or metroprolol succinate |
Timeline
- Start date
- 2020-01-01
- Primary completion
- 2021-01-01
- Completion
- 2025-01-01
- First posted
- 2020-01-09
- Last updated
- 2020-01-09
Source: ClinicalTrials.gov record NCT04221919. Inclusion in this directory is not an endorsement.